- Launch of new Company Long Term Incentive Plan
- Appointment of Non-Executive Director
- Progression of patient cohorts in PROTECT Trial
- Successful meetings with Paul Ehrlich Institut
- Allergy Therapeutics presents findings at EAACI
- Further detail from G306 Phase III field trial
- Director Resignation
- Interim Results for six months ended 31 Dec 2023
- Update on funding
- VLP Peanut PROTECT Trial Update
More ▼
Key statistics
On Friday, Allergy Therapeutics PLC (AGY:LSE) closed at 4.75, -24.60% below its 52-week high of 6.30, set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.75 |
---|---|
High | 4.80 |
Low | 4.75 |
Bid | 4.30 |
Offer | 5.30 |
Previous close | 4.80 |
Average volume | 225.24k |
---|---|
Shares outstanding | 4.77bn |
Free float | 336.83m |
P/E (TTM) | -- |
Market cap | 226.41m GBP |
EPS (TTM) | -0.0266 GBP |
Data delayed at least 20 minutes, as of Jul 05 2024 15:13 BST.
More ▼
Investors Chronicle View
The last IC recommendation on Allergy Therapeutics PLC shares was Hold at 13.00 on 25 Sep 2019Read the full article